Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
Sponsor: ScandiBio Therapeutics AB
Collaborators: Istanbul Medipol University Hospital, Istanbul Umraniye Training and Research Hospital, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Bagcilar Training and Research Hospital, Kanuni Sultan Suleyman Training and Research Hospital, Alanya Alaaddin Keykubat University Alanya Training and Research Hospital, Canakkale 18 Mart University Health Research and Application Hospital
Purpose
To assess the clinical efficacy of the combination of metabolic cofactors supplementation (N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine) and hydroxychloroquine in COVID-19 patients.
Study Design
Open label, randomized, controlled, investigator-initiated, multi-center trial
Dose
L-Carnitine tartrate, 7.46 g/day plus N-Acetylcysteine, 5.1 g/day plus Nicotinamide riboside, 2 g/day plus Serine 24.7 g/day
Length of Intervention
14 days
Intrinsic Capacity
Vitality
Status
Recruiting
Condition or Disease
COVID-19
Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.